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A B S T R A C T
Cytokineshave been shown to inﬂuence susceptibility to febrile seizures and epilepsy. In this study, the role
of interleukin-1b (IL-1b)was examined indeveloping rats. IL-1b and interleukin-1 receptor antagonist (IL-
1ra) were administered to developing rats, and seizures were induced by moist warm air. Twenty male
Lewis rats (21–23 days old) were divided into two groups (IL-1b and saline control groups) and two holes
were made in the skull for EEG electrodes. We applied human recombinant IL-1b intra-nasally 1 h before
seizures induced bymoistwarm air. The brain temperature at the appearance of seizure discharges on EEG,
and the latency time from the hyperthermia onset until the appearance of seizure discharges on EEG were
measured. And the same study using IL-1ra was performed. The median brain temperature for the IL-1b
group, 42.6 8C (range: 41.8–43.0), was signiﬁcantly lower than that for the control, 42.9 (42.3–43.4)
(P = 0.043). The brain temperature for the IL-1ra group, 43.3 (42.8–43.7), was signiﬁcantly higher than that
for the control, 42.9 (42.2–43.5) (P = 0.011), and the latency time for the IL-1ra group, 398 s (270–561),was
signiﬁcantly longer than that for the control, 325 (252–462) (P = 0.035). These results demonstrate that IL-
1b promotes hyperthermia-induced seizures in developing rats.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Febrile seizure (FS) is the most common convulsive disorder in
children. More than 5% of the normal population have experienced
at least one febrile seizure, with as much as 7–14% estimated for
Japan and the Paciﬁc islands.1 Although FS does not generally
induce long-term brain damage or cognitive deﬁcits, several
retrospective studies have demonstrated a signiﬁcant relationship
between a history of prolonged FS during early childhood and
mesial temporal sclerosis, which is responsible for intractable
temporal lobe epilepsy.2
The pathogenesis of FS remains unknown. Several previous
studies have reported that various inﬂammatory cytokines play an
important role in host defense responses during infections. In
addition, they can act as endogenous pyrogens and their levels are
elevated in plasma or cerebrospinal ﬂuid (CSF) of patients with FS
or epileptic seizures.3–6 Among them, interleukin-1b (IL-1b) is
thought to be an important cytokine in FS, because high levels of IL-
1b have been observed in the CSF of FS patients.7 However, it could* Corresponding author. Tel.: +81 89 960 5320; fax: +81 89 960 5941.
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doi:10.1016/j.seizure.2008.10.001not be determined whether increased or decreased cytokine levels
were a result or cause of central nervous system disease. Blood and
CSF samples are usually collected once disease symptoms are
detected, and the levels of some inﬂammatory cytokine mRNAs,
which are associated with cytokine production, become elevated
with electrical stimulated experimental seizures.8
Recently, the role of genetic polymorphism of cytokines in the
pathogenesis of FS has been analyzed. A previous case–control
study of Japanese FS patients demonstrated that the 511C/T
polymorphism of the IL1B gene was associated with development
of simple FS with sporadic occurrence.9 However, an additional
study reported no signiﬁcant relationship between the production
of IL-1b and the development of FS.10
Hyperthermia is a strong, precipitating factor for the induction
of seizures. Seizures are often induced by febrile episodes in
patients with a positive history of severe, febrile seizure, severe
myoclonic epilepsy in infancy, or speciﬁc subtypes of childhood
epilepsy.11 Experimental hyperthermia-induced seizures (HS)
have been used in animal models to clarify the mechanisms
involved in FS.12–15 A previous study, using immature, transgenic
rodents, demonstrated that IL-1b receptor-deﬁcient mice are
resistant to experimental HS.16 On the contrary, IL-1b exhibited an
anti-epileptic role in a rat seizure model.17 The present studyvier Ltd. All rights reserved.
Fig. 1. EEG ﬁndings in rats after warming. Moderate sustained irregular 5–8 Hz
activities were measured prior to warming (A). Spikes and spike-wave bursts were
induced several minutes after warming with moist, warm air (B).
Fig. 2. Brain temperature at seizure onset, as well as seizure latency, after
administration of IL-1b. The data are presented as the median and range. The brain
temperature of the IL-1b group, 42.6 8C (range: 41.8–43.0), was signiﬁcantly less
than the control group, 42.9 (42.3–43.3) (P = 0.043) (A). There was no signiﬁcant
difference between latency time of the IL-1b group, 296 s (244–447), and the
control group, 366 (298–440) (P = 0.052) (B).
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1ra) in HS of developing rats.
2. Materials and methods
2.1. Animals
Male, Lewis rat pups (21–23 days old) were kept with their
mothers in standard, housing conditions, including a 12-h light/12-
h dark cycle, controlled temperature, and free access to food and
water during the entire experimental period. All experimental
procedures conformed to guidelines from the Ministry of Educa-
tion of Japan, and were approved by the animal experimental
committee of Ehime University Graduate School of Medicine (No.
TE-17-2).
2.2. Preparation for recording electroencephalography and brain
temperature
A stereotaxic holder (Narishige Co., Ltd., Tokyo, Japan) was used
to ﬁx the head in place. Two holes were made in the skull over the
right frontal and occipital cortex for placement of silver electro-
encephalography (EEG) electrodes and plastic receptacles (Unique
Medical Co., Ltd., Tokyo, Japan). An additional hole was made over
the left, central cortex for placement of the needle brain
temperature thermometer (Unique Medical Co., Ltd.). These
manipulations were performed under anesthesia with an intra-
peritoneal injection of pentobarbital sodium (Dainippon Pharma
Co., Ltd., Osaka, Japan, 30 mg/kg). Cefotaxime sodium (Aventis
Pharma Co., Ltd., Tokyo, Japan), 500 mg/kg, was intraperitoneally
injected to prevent bacterial infections.
2.3. Drug application and induction of hyperthermia-induced seizures
Twenty male, Lewis rats were divided into two groups 72 h
after surgery: IL-1b (n = 10) and control (n = 10) groups. Recom-
binant human IL-1b (500 ng; Bender MedSystems, Vienna,
Austria) was dissolved in 0.9% saline for a total volume of 20 ml
and administered intranasally to rats in the IL-1b group. Rats in the
control group received only 0.9% saline. The intranasal adminis-
tration method was based on previous studies that demonstrated
the effectiveness of this method.18 One hour after intranasal
administration of recombinant human IL-1b or saline, each rat was
placed in a special, plastic cage. HS was induced by moist warm air
(45–50 8C), followed by EEG monitoring. Brain temperature was
measured at the onset of seizure discharge, based on EEG, and
latency time was recorded from the onset of hyperthermia until
the appearance of seizure discharges on EEG.
In the second experimental design, an additional 20male, Lewis
rats were divided into two groups: IL-1ra (n = 10) and control
(n = 10). Recombinant human IL-1ra (500 ng: BenderMedSystems)
or saline was intranasally applied 1 h prior to moist, warm air-
induced seizures. Brain temperature and latency time were
measured, according to the above-described methods.
2.4. Measurement of IL-1b concentration
A third experiment was designed to measure IL-1b concentra-
tions in the central nervous system, which consisted of male, Lewis
rats divided into two groups: IL-1b (n = 5) and control (n = 5).
Recombinant human IL-1b (500 ng) or saline was intranasally
administered. One hour later, each rat was anesthetized with
diethyl ether (Kanto Chemical Co., Inc., Tokyo, Japan), and the brain
was quickly removed. The frontal lobes (anterior to the optic
chiasma) were isolated and stored at 80 8C until further use.Samples were weighed and homogenized in 50 mM PBS (pH 7.4).
Thereafter, they were centrifuged for 15 min (5000 rpm), and the
supernatants were harvested and stored. IL-1b Human Easy ELISA
(Amersham Biosciences UK Ltd., Buckinghamshire, England) was
performed to determine human IL-1b levels in the frontal lobe. The
IL-1b detection level of this ELISA was determined to be 1.1 pg/ml.
2.5. Statistics
Mann-Whitney U-test was performed for statistical analysis in
this study. Values were expressed median (range), and a P-value of
<0.05 was considered to be signiﬁcant.
3. Results
3.1. Brain temperature at seizure onset and latency times
All experimental rats suffered from stereotypical seizures
during hyperthermia, and completely recovered following the
seizures. During a typical seizure, all movements abruptly stopped,
and the rat displayed a tonic posture. Later in the course of
seizures, facial clonus appeared and spread to generalized, clonic
movement. Background EEG activity, prior to HS, consisted of
moderate, sustained, irregular, theta rhythm (Fig. 1A). Spikes and
spike-wave bursts, which were consistent with clinical seizures,
were induced for several minutes after warming by moist, warm
air (Fig. 1B).
As shown in Fig. 2A, the median brain temperature at seizure
onset of the IL-1b group, 42.6 8C (range: 41.8–43.0), was
signiﬁcantly less than the control group, 42.9 (42.3–43.4)
(P = 0.043). However, in terms of latency time, there was no
difference between the two groups, 296 s (244–447) vs. 366 s
(298–440) (P = 0.052) (Fig. 2B). Following administration of IL-1ra,
however, signiﬁcantly elevated the brain temperature in the IL-1ra
Fig. 3. Brain temperature at seizure onset, as well as seizure latency, after
administration of IL-1ra. The data are presented as the median and range. The brain
temperature for the IL-1ra group, 43.3 8C (42.8–43.7), was signiﬁcantly higher than
the control group 42.9 (42.2–43.5) (P = 0.011) (A); latency time for the IL-1ra group,
398 s (270–561), was signiﬁcantly longer than the control group, 325 (252–462)
(P = 0.035) (B).
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(42.2–43.5) (P = 0.011) (Fig. 3A). In addition, latency time was
signiﬁcantly longer in the IL-1ra group, 398 s (270–561), compared
to the control group, 325 (252–462) (P = 0.035) (Fig. 3B).
3.2. IL-1b concentration
Following administration of recombinant human IL-1b, the
median IL-1b protein concentrations was signiﬁcantly greater in
the frontal lobes of IL-1b-treated rats, 288 pg/mg (range: 222–
534), compared to control rats, 60 (48–156) (P = 0.008) (data not
shown).
4. Discussion
The present study demonstrated that intranasal administration
of IL-1b decreased brain temperature at seizure onset, whereas IL-
1ra increased brain temperature and also extended the seizure
latency time. Previous transgenic studies have shown that IL-1b
receptor-deﬁcient mice are resistant to experimental FS, and high
doses of IL-1b-induced seizures only in IL-1b receptor-expressing
mice.16 Moreover, intracerebroventricular application of patholo-
gical amounts of IL-1b resulted in an increased number of
convulsing animals during fever.19 Experimental seizures could be
suppressed in mice through the use of intracerebroventricular or
intracerebral application of recombinant IL-1ra, as well as selective
overexpression of IL-1ra.19,20 IL-1b, however, has been shown to
exhibit antiepileptic and neuroprotective roles in a rat amygdala-
kindling model.17 These conﬂicting ﬁndings could be explained by
different pathophysiological mechanisms of seizures.
In cultured hippocampal neurons, IL-1b has been reported to
suppress the function of gamma-aminobutyric acid type A (GABAA)
receptors through the involvement of a non-speciﬁc kinase.21
GABA is one of the major inhibitory neurotransmitters in the
central nervous system, and GABAA receptor antagonists enhance
experimental HS in developing rats.22 Conversely, studies using
primary cultured hippocampal neurons have shown that IL-1b
enhances the function of N-methyl-D-aspartate (NMDA) receptor
by activating tyrosine kinases and subsequent phosphorylation of
NMDA receptors 2A/B subunit.23 A NMDA receptor blocker was
also shown to suppress HS and HS-kindling in developing rats.24
Therefore, IL-1b might inﬂuence seizure susceptibility through
functional involvement of excitatory and inhibitory neurotrans-
mitters, because it not only enhances neuronal excitability, but
also induces structural and functional changes in glial and
neuronal networks, which are responsible for mesial temporal
lobe epilepsy.25 On the other hand, in adult rat seizure studies
induced by electrical stimulation and kindling model, earlyanticonvulsive effects of IL-1b were completely suppressed by
treatment with inhibitors of nitric oxide and prostaglandin
synthesis, such as NG-nitro-L-arginine-methyl ester (L-NAME)
and piroxicam, respectively.17 Therefore, it was suggested that
nitric oxide and prostaglandins are involved in the IL-1b antic-
onvulsant effect in fully kindled mature brains.
An important issue in the study of hyperthermia-induced
seizures is to use the appropriate age of animal models. In terms of
brain development, the rat brain at postnatal days 12–13
corresponds to a full-term, newborn, human brain26; and postnatal
day 20 is the typical weaning age for rats. Because human FS most
commonly occurs between the ages of 6months to 5 years, the 21–
23-day-old rat would be one of themore appropriatemodel age for
studying FS in childhood.
The present study also employed intranasal administration of
recombinant human IL-1b and IL-1ra, which has been reported to
be an appropriate method to allow cytokines and polypeptides to
bypass the blood–brain barrier.27,28 This method has also been
used to study the inﬂuence of IL-6 on seizure susceptibility in an
experimental model.18 In addition, we have previously conﬁrmed
that intranasal administration of IL-6 and IL-10 decreased seizure
irritability of HS in developing rats.29 In experiments using
intranasal administration of a radioactive peptide, analysis
conﬁrmed the presence of the peptide in the cerebellum, the
midbrain (including amygdaloid nuclei), olfactory bulbs, and
frontal cortex. Additionally, when the peptide was administered
intranasally, local redistribution took place, resulting in nasal
absorption via brain blood microcirculation to BBB-lacking brain
areas, such as the circumventricular organs.30 Amygdala and
hippocampal neuronal activity has been demonstrated to be
important for inducing experimental FS15,31; therefore, intaranasal
administration is considered to be one of the more suitable
methods for studies of human FS.
Intranasal administration of IL-1b and IL-1ra was used in
immature rats to examine the role of these cytokines in the
induction of HS. The present results veriﬁed that IL-1b enhanced,
and IL-1ra suppressed, susceptibility of HS in immature rats. These
results could provide insight for future studies of human febrile
seizures.
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